Litcius/Paper detail

PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking

Claire Lugnier, Hayder M. Al‐kuraishy, Éric Rousseau

2021Biochemical Pharmacology63 citationsDOIOpen Access PDF

Topics & Concepts

ARDSInflammationDownregulation and upregulationPathogenesisCoronavirus disease 2019 (COVID-19)Angiotensin-converting enzyme 2MedicinePneumoniaPhosphodiesteraseAngiotensin IILungImmunologyRenin–angiotensin systemPharmacologyInternal medicineChemistryEnzymeReceptorBiochemistryDiseaseInfectious disease (medical specialty)GeneBlood pressurePhosphodiesterase function and regulationCholinesterase and Neurodegenerative DiseasesDiverse Scientific Research Studies
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking | Litcius